Edit
LivaNova
https://www.livanova.com/en-us/home/obstructive-sleep-apnea.aspxLast activity: 16.06.2026
Probably Closed
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.
At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach.
We are a market leader with a workforce of approximately 3,000 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries.
At LivaNova, we serve health and improve lives. Day by day. Life by life.
At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach.
We are a market leader with a workforce of approximately 3,000 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries.
At LivaNova, we serve health and improve lives. Day by day. Life by life.
Location: United Kingdom
Employees: 1001-5000
Phone: +1 281-228-7200
Founded date: 2015
Mentions in press and media 27
| Date | Title | Description |
| 16.06.2026 | LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patient... |
| 11.06.2026 | Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10. “We’re pleased to we... |
| 05.06.2026 | LivaNova Appoints Anne Liddy as Chief Legal Officer | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and s... |
| 21.05.2026 | LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on ... |
| 19.05.2026 | LivaNova to Present at Goldman Sachs Global Healthcare Conference in June | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of Liv... |
| 25.03.2026 | LivaNova to Announce First-Quarter 2026 Results | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will rel... |
| 19.03.2026 | LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderat... |
| 20.01.2026 | LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The... |
| 25.12.2025 | Global Innovators Converge: J.P. Morgan Conference Spotlights LivaNova, Hansa Biopharma | Global medical technology leader LivaNova and biopharma innovator Hansa Biopharma prepare for the prestigious J.P. Morgan 44th Annual Healthcare Conference. Both companies will present their strategic visions and latest advancements. LivaNo... |
| 23.12.2025 | LivaNova to Present at J.P. Morgan Healthcare Conference in January | LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and A... |
Show more